Latest revenue
$26.2M
as of 2026-03-31
Latest net income
$-71.6M
as of 2026-03-31
Net margin
-273.1%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AUTL is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $407.2M
- Enterprise value
- $276.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 3.74×
- Dividend yield
- 0.0%
- 52-wk high
- $2.70
- 52-wk low
- $1.18
- Beta
- —
- Shares out
- 266.2M
5-year trend
What this company does
Item 1. Business Business Overview We are an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune diseases. Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate target cells. We believe our programmed T cell therapies have the potential to be best-in-class and offer patients substantial benefits over the existing standard of care, including the potential for cure in…
AI summary unavailable — showing raw filing excerpt
Generated from AUTL's filing dated 2026-03-27
Key risks
Item 1A. Risk Factors Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Annual Report, including our financial statements and related notes, in evaluating our business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price our ADSs could decline. Risks Related to Our Financial…
AI summary unavailable — showing raw filing excerpt
Generated from AUTL's filing dated 2026-03-27
Profitability
Operating margin
-358.9%
51.9%Net margin
-381.4%
44.1%Return on equity
-161.4%
212.6%Return on assets
-48.8%
73.1%Leverage
Debt / equity
2.31×
177.4%Debt / assets
69.8%
53.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $26.2M | +191.9% | $-71.6M | -2.0% | -273.1% |
Q4 2025 2025-12-31 | $24.3M | +9.1% | $-90.3M | -227.2% | -371.9% |
Q3 2025 2025-09-30 | $21.2M | — | $-79.1M | +3.6% | -373.3% |
Q2 2025 2025-06-30 | $20.9M | — | $-47.9M | +17.8% | -229.0% |
Q1 2025 2025-03-31 | $9.0M | -11.0% | $-70.2M | -33.2% | -781.1% |
Q4 2024 2024-12-31 | $22.3M | — | $-27.6M | — | -124.0% |
Q3 2024 2024-09-30 | $0 | -100.0% | $-82.1M | -79.1% | — |
Q2 2024 2024-06-30 | $0 | — | $-58.3M | -27.9% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on AUTL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for AUTL in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns AUTL
Institutional value
$10.8M
Total shares held
8.0M
Distinct holders
39
-49 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 1.5M | $2.0M | -2.2M (-59.8%) | Trimmed |
| 2 | UBS Group AG | 1.3M | $1.8M | +428.7K (+48.9%) | Added |
| 3 | Cetera Investment Advisers | 1.1M | $1.6M | +29.3K (+2.7%) | Added |
| 4 | JPMORGAN CHASE & CO | 935.4K | $1.2M | -43.9K (-4.5%) | Trimmed |
| 5 | Alphabet Inc. | 698.3K | $963.6K | +0 (+0.0%) | No change |
| 6 | Marex Group plc | 542.9K | $749.1K | — | New |
| 7 | Privium Fund Management B.V. | 363.4K | $501.5K | +37.2K (+11.4%) | Added |
| 8 | JANE STREET GROUP, LLC | 245.8K | $339.2K | -435.2K (-63.9%) | Trimmed |
| 9 | WELLS FARGO & COMPANY/MN | 207.9K | $286.8K | +10.8K (+5.5%) | Added |
| 10 | Erste Asset Management GmbH | 195.0K | $247.7K | +0 (+0.0%) | No change |
| 11 | Aubrey Capital Management Ltd | 130.0K | $180.1K | -95.2K (-42.3%) | Trimmed |
| 12 | Clearstead Advisors, LLC | 121.1K | $167.1K | +0 (+0.0%) | No change |
| 13 | Leonteq Securities AG | 100.0K | $138.0K | +0 (+0.0%) | No change |
| 14 | SmartHarvest Portfolios, LLC | 59.2K | $81.7K | +37.8K (+177.0%) | Added |
| 15 | Invesco Ltd. | 53.2K | $73.4K | +1.5K (+2.9%) | Added |
| 16 | Caitong International Asset Management Co., Ltd | 51.6K | $71.2K | -239.0K (-82.2%) | Trimmed |
| 17 | R Squared Ltd | 39.6K | $54.6K | +12.9K (+48.4%) | Added |
| 18 | LPL Financial LLC | 37.6K | $51.9K | -5.0K (-11.7%) | Trimmed |
| 19 | China Universal Asset Management Co., Ltd. | 35.6K | $49.1K | +2.9K (+8.9%) | Added |
| 20 | RHUMBLINE ADVISERS | 35.0K | $48.2K | +2.7K (+8.4%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AUTL's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.